In fall of 2017, JLLC NatiVita will begin studies of innovative drugs for the treatment of skin and breast cancer, announced Alexey Sychev, the Chairman of the Board of the company.
“The company was established not only to manufacture and sell drugs for the treatment of malignant tumors, but also to invest in our own scientific developments and joint research with strategic partners by including the company in preclinical studies and clinical trials of developed innovative drugs,” said Alexey Sychev. “Together with BIOCAD (Russia), we are implementing research programs for several products included in the state program of pharmaceutical industry development for 2016-2020. In the area of oncology, this involves the products for the treatment of malignant melanoma (skin cancer), as well as a drug for the treatment of breast cancer. The studies of these drugs will begin this fall.”
He added that the drugs have passed preclinical studies and clinical trials Phase I, which confirmed their safety.
Alexey Sychev said that his company has the capability to conduct its own studies, although he noted that, today, for a single pharmaceutical company, no matter where it is located, it is very difficult to produce an innovative product independently. He is convinced that only the collaboration of experts, scientists, manufacturers from different countries can allow to create something absolutely new for the therapy of malignant human tumors.